AIM ImmunoTech Inc. — Director's Dealing 2018

Mar 1, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-02-13

Reporting Person: Pascale Adam (CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-13	Options to buy Common Stock	$0.37	A	123874	Acquired	2028-02-13	Common Stock (123874)	Direct

Footnotes

F1: This option is being issued to senior management in exchange for a voluntary 40% deferral in salary.